Willfact

Willfact (Human Von Willebrand Factor) is a plasma-derived therapy for von Willebrand disease, supporting clotting factor replacement. Used to manage bleeding episodes and surgical prophylaxis in VWD patients. Short-term solution for clotting disorders.

Willfact is used to treat and prevent bleeding in patients with von Willebrand disease, a condition where blood does not clot properly. It may also be used before medical procedures to reduce bleeding risk. This therapy replaces missing or defective von Willebrand factor, a protein essential for blood clotting. It is not a cure but helps manage symptoms during active treatment periods.

Willfact works by temporarily increasing levels of von Willebrand factor in the bloodstream, which helps blood clot more effectively. Users may notice reduced bleeding episodes or faster clotting during treatment. Effects vary by individual and depend on the condition being managed.

Store Willfact as directed by healthcare providers, typically refrigerated but not frozen. Protect from light and keep out of reach of children. Use only as prescribed and report any unusual reactions. Do not use if the solution is discolored or contains particles. Always follow medical guidance for administration timing and storage.

Willfact may interact with other clotting therapies or medications affecting blood viscosity. Avoid alcohol and herbal supplements unless approved by a healthcare professional. Inform providers about all current medications to assess potential interactions. No known severe interactions have been widely reported, but individual responses may vary.